Cerebral near infrared spectroscopy oximetry in extremely preterm infants: Phase II randomised clinical trial

  • Simon Hyttel-Sorensen
  • , Adelina Pellicer
  • , Thomas Alderliesten
  • , Topun Austin
  • , Frank Van Bel
  • , Manon Benders
  • , Olivier Claris
  • , Eugene Dempsey
  • , Axel R. Franz
  • , Monica Fumagalli
  • , Christian Gluud
  • , Berit Grevstad
  • , Cornelia Hagmann
  • , Petra Lemmers
  • , Wim Van Oeveren
  • , Gerhard Pichler
  • , Anne Mette Plomgaard
  • , Joan Riera
  • , Laura Sanchez
  • , Per Winkel
  • Martin Wolf, Gorm Greisen

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To determine if it is possible to stabilise the cerebral oxygenation of extremely preterm infants monitored by cerebral near infrared spectroscopy (NIRS) oximetry. Design: Phase II randomised, single blinded, parallel clinical trial. Setting Eight tertiary neonatal intensive care units in eight European countries. Participants: 166 extremely preterm infants born before 28 weeks of gestation: 86 were randomised to cerebral NIRS monitoring and 80 to blinded NIRS monitoring. The only exclusion criterion was a decision not to provide life support. Interventions: Monitoring of cerebral oxygenation using NIRS in combination with a dedicated treatment guideline during the first 72 hours of life (experimental) compared with blinded NIRS oxygenation monitoring with standard care (control). Main outcome measures: The primary outcome measure was the time spent outside the target range of 55-85% for cerebral oxygenation multiplied by the mean absolute deviation, expressed in %hours (burden of hypoxia and hyperoxia). One hour with an oxygenation of 50% gives 5%hours of hypoxia. Secondary outcomes were all cause mortality at term equivalent age and a brain injury score assessed by cerebral ultrasonography. Randomisation: Allocation sequence 1:1 with block sizes 4 and 6 in random order concealed for the investigators. The allocation was stratified for gestational age (<26 weeks or ≥26 weeks). Blinding: Cerebral oxygenation measurements were blinded in the control group. All outcome assessors were blinded to group allocation. Results: The 86 infants randomised to the NIRS group had a median burden of hypoxia and hyperoxia of 36.1%hours (interquartile range 9.2-79.5%hours) compared with 81.3 (38.5-181.3) %hours in the control group, a reduction of 58% (95% confidence interval 35% to 73%, P<0.001). In the experimental group the median burden of hypoxia was 16.6 (interquartile range 5.4-68.1) %hours, compared with 53.6 (17.4-171.3) %hours in the control group (P=0.0012). The median burden of hyperoxia was similar between the groups: 1.2 (interquartile range 0.3-9.6) %hours in the experimental group compared with 1.1 (0.1-23.4) %hours in the control group (P=0.98). We found no statistically significant differences between the two groups at term corrected age. No severe adverse reactions were associated with the device. Conclusions: Cerebral oxygenation was stabilised in extremely preterm infants using a dedicated treatment guideline in combination with cerebral NIRS monitoring. Trial registration: ClinicalTrial.gov NCT01590316.

Original languageEnglish
Article numberg7635
JournalBMJ
Volume350
DOIs
Publication statusPublished - 5 Jan 2015

Fingerprint

Dive into the research topics of 'Cerebral near infrared spectroscopy oximetry in extremely preterm infants: Phase II randomised clinical trial'. Together they form a unique fingerprint.

Cite this